The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.
about
Practical combination therapy based on pathophysiology of type 2 diabetesEmerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetesPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes.Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications.Newer therapeutic options for children with diabetes mellitus: theoretical and practical considerations.Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes.Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.Review of sitagliptin phosphate: a novel treatment for type 2 diabetes.Incretin-based therapies in type 2 diabetes mellitus.Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions.Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes.Diabetes, hypertension, and chronic kidney disease progression: role of DPP4.Durability of response to dapagliflozin: a review of long-term efficacy and safety.One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins.Mechanism of action of DPP-4 inhibitors--new insights.Intraportal GLP-1 stimulates insulin secretion predominantly through the hepatoportal-pancreatic vagal reflex pathways.Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus.Inhibition of dipeptidyl peptidase IV (DPP-IV) by tryptophan containing dipeptides.Angiotensin Converting Enzyme and Dipeptidyl Peptidase-IV Inhibitory, and Antioxidant Activities of a Blue Mussel (Mytilus edulis) Meat Protein Extract and Its Hydrolysates
P2860
Q28076530-0CFF6551-86E5-415A-80E4-D49D84A333DAQ28762629-B8EF34BD-8375-45AA-A556-B220F4004048Q30249371-DAAEB35D-70AD-4BE7-A1F9-09521F1F34D6Q33973990-BD064A94-B85C-4F18-BDFF-72936A6F9686Q34620636-2FCAE9D9-85AD-4C65-A690-C6070253637AQ35125198-DDAD4319-6112-4C8E-8815-17CAB5E04C49Q36455865-DBF9C59E-ACE3-459E-BF52-DA0824C6175FQ36580608-751471FC-DD73-4A19-B783-203528A8B5EBQ36735761-60D2A97E-B6CE-4DF9-95D8-122E436D5697Q36854023-66EFD71A-20D2-4636-A369-4DF8E500826BQ36964866-BA128CDE-2A93-4212-88CE-4FD37DAA7DF7Q37825941-3E5E80C8-9EB7-4BD2-ADB8-9EB101D9A722Q38264456-2BFFD848-395A-4DF4-B54D-F0F2493FFAA5Q38603506-F9063445-6569-4CCC-AB3E-84B9D0B0B07AQ39103371-34C050B2-6BA3-4D66-8075-7BCACAA56992Q39430445-C0951CEF-49AD-485F-B100-D2F499B14C7BQ40617003-4DF63D2C-BE38-4DA9-98CE-4B2F1A1F3352Q41883921-7896DAEB-1249-4D05-BA65-CB6F08CDD940Q42078124-D3435955-FCC2-4D15-A6C9-8485E14B8901Q43235398-7445DBDF-A482-49C5-9BBF-66429FAFDBAAQ44093898-095B03AF-D89E-41AC-9DBA-DD573D6B1B7DQ44814545-6A6F2E85-5027-477E-AD60-5964DC20A6E2Q45000251-27096522-A4F6-4C6F-8E4B-5C19220BB710Q58835718-BE4C26DB-0E80-49E1-B70A-85D9A2F8D3E3
P2860
The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.
@en
The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.
@nl
type
label
The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.
@en
The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.
@nl
prefLabel
The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.
@en
The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.
@nl
P1433
P1476
The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.
@en
P2093
A El-Ouaghlidi
P2888
P304
P356
10.1007/S00125-005-1704-8
P577
2005-03-11T00:00:00Z